Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;77(6):355-366.
doi: 10.1097/OGX.0000000000001033.

Recent Advances in Treatment of Recurrent Spontaneous Abortion

Affiliations
Review

Recent Advances in Treatment of Recurrent Spontaneous Abortion

Tianqing Deng et al. Obstet Gynecol Surv. 2022 Jun.

Abstract

Importance: Recurrent spontaneous abortion (RSA) is a distressing condition experienced by approximately 1% of women trying to conceive. However, the treatment of RSA is a challenge both for clinicians and patients.

Objective: The aim of this review is to discuss the medical and surgical approach to the management of RSA, including those caused by anatomical, genetic, male, infectious, endocrine, and immune factors.

Evidence acquisition: A literature search using MeSH terms for each topic was undertaken using PubMed, supplemented by hand searching for additional references. Retrieved articles were reviewed, synthesized, and summarized.

Results: Available treatments target hypothetical risk factors for RSA, although the effectiveness of many treatment options is controversial. Intervention should depend on the benefit-to-risk ratio of the proposed treatment.

Conclusions and relevance: The etiology of RSA is heterogeneous, and patients often lack specific clinical manifestations, which has hindered the progress in predicting and preventing RSA to some extent. Despite intensive workup, at least 50% of couples do not have a clear underlying pathology. In addition, an evidence-based treatment is not available in most patients even if abnormal test results are present. Many new treatment directions are also still actively exploring; empirical and combined multiple treatments are still the main methods.

PubMed Disclaimer

References

    1. ESHRE Guideline Group on RPL, Bender Atik R Christiansen OB Elson J, et al. ESHRE guideline: recurrent pregnancy loss. Hum Reprod Open. 2018;2018:hoy004. - PMC - PubMed
    1. Practice Committee of the American Society for Reproductive Medicine . Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2012;98:1103–1111. - PubMed
    1. Abdollahi E Tavasolian F Ghasemi N, et al. Association between lower frequency of R381Q variant (rs11209026) in IL-23 receptor gene and increased risk of recurrent spontaneous abortion (RSA). J Immunotoxicol. 2015;12:317–321. - PubMed
    1. Turocy JM, Rackow BW. Uterine factor in recurrent pregnancy loss. Semin Perinatol. 2019;43:74–79. - PubMed
    1. Jaslow CR. Uterine factors. Obstet Gynecol Clin North Am. 2014;41:57–86. - PubMed